nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—PTGIS—endothelium—colon cancer	0.0482	0.145	CbGeAlD
Epoprostenol—PTGIS—blood vessel—colon cancer	0.0444	0.134	CbGeAlD
Epoprostenol—PTGIS—gall bladder—colon cancer	0.0418	0.126	CbGeAlD
Epoprostenol—PTGIR—endothelium—colon cancer	0.0277	0.0834	CbGeAlD
Epoprostenol—CYP2C9—Capecitabine—colon cancer	0.0256	0.628	CbGbCtD
Epoprostenol—PTGIR—blood vessel—colon cancer	0.0255	0.0769	CbGeAlD
Epoprostenol—PTGIS—smooth muscle tissue—colon cancer	0.0208	0.0628	CbGeAlD
Epoprostenol—P2RY12—epithelium—colon cancer	0.0195	0.0587	CbGeAlD
Epoprostenol—PTGER1—renal system—colon cancer	0.0187	0.0562	CbGeAlD
Epoprostenol—CYP2C9—Fluorouracil—colon cancer	0.0152	0.372	CbGbCtD
Epoprostenol—PTGIR—epithelium—colon cancer	0.0124	0.0374	CbGeAlD
Epoprostenol—PTGIS—liver—colon cancer	0.0123	0.0369	CbGeAlD
Epoprostenol—PTGIR—smooth muscle tissue—colon cancer	0.012	0.0361	CbGeAlD
Epoprostenol—PTGIR—renal system—colon cancer	0.0115	0.0347	CbGeAlD
Epoprostenol—PTGIR—digestive system—colon cancer	0.00945	0.0285	CbGeAlD
Epoprostenol—PTGIS—lymph node—colon cancer	0.0094	0.0283	CbGeAlD
Epoprostenol—PTGIR—liver—colon cancer	0.00704	0.0212	CbGeAlD
Epoprostenol—PTGIR—lymph node—colon cancer	0.0054	0.0163	CbGeAlD
Epoprostenol—PTGIS—Nicotinamide salvaging—PTGS2—colon cancer	0.00498	0.156	CbGpPWpGaD
Epoprostenol—CYP2C9—digestive system—colon cancer	0.00338	0.0102	CbGeAlD
Epoprostenol—PTGIS—Nicotinate metabolism—PTGS2—colon cancer	0.00265	0.0831	CbGpPWpGaD
Epoprostenol—CYP2C9—liver—colon cancer	0.00252	0.00758	CbGeAlD
Epoprostenol—PTGIS—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—colon cancer	0.00219	0.0685	CbGpPWpGaD
Epoprostenol—Angiopathy—Vincristine—colon cancer	0.00185	0.00311	CcSEcCtD
Epoprostenol—Cardiac disorder—Irinotecan—colon cancer	0.00184	0.00309	CcSEcCtD
Epoprostenol—Flushing—Irinotecan—colon cancer	0.00184	0.00309	CcSEcCtD
Epoprostenol—Mediastinal disorder—Vincristine—colon cancer	0.00184	0.00309	CcSEcCtD
Epoprostenol—Angiopathy—Irinotecan—colon cancer	0.0018	0.00302	CcSEcCtD
Epoprostenol—Mediastinal disorder—Irinotecan—colon cancer	0.00179	0.003	CcSEcCtD
Epoprostenol—Mental disorder—Vincristine—colon cancer	0.00179	0.003	CcSEcCtD
Epoprostenol—Chills—Irinotecan—colon cancer	0.00178	0.00299	CcSEcCtD
Epoprostenol—Orthostatic hypotension—Capecitabine—colon cancer	0.00175	0.00295	CcSEcCtD
Epoprostenol—Pulmonary oedema—Methotrexate—colon cancer	0.00175	0.00294	CcSEcCtD
Epoprostenol—Back pain—Vincristine—colon cancer	0.00172	0.00288	CcSEcCtD
Epoprostenol—Sepsis—Methotrexate—colon cancer	0.00171	0.00287	CcSEcCtD
Epoprostenol—Flatulence—Irinotecan—colon cancer	0.0017	0.00286	CcSEcCtD
Epoprostenol—Gastritis—Capecitabine—colon cancer	0.0017	0.00285	CcSEcCtD
Epoprostenol—Back pain—Irinotecan—colon cancer	0.00167	0.00281	CcSEcCtD
Epoprostenol—Abdominal distension—Capecitabine—colon cancer	0.00167	0.00281	CcSEcCtD
Epoprostenol—Muscle spasms—Irinotecan—colon cancer	0.00166	0.00279	CcSEcCtD
Epoprostenol—Anaemia—Vincristine—colon cancer	0.00164	0.00275	CcSEcCtD
Epoprostenol—Agitation—Vincristine—colon cancer	0.00163	0.00274	CcSEcCtD
Epoprostenol—Anaemia—Irinotecan—colon cancer	0.0016	0.00268	CcSEcCtD
Epoprostenol—Abdominal discomfort—Capecitabine—colon cancer	0.00159	0.00267	CcSEcCtD
Epoprostenol—Hepatic failure—Methotrexate—colon cancer	0.00159	0.00267	CcSEcCtD
Epoprostenol—Pancytopenia—Capecitabine—colon cancer	0.00158	0.00265	CcSEcCtD
Epoprostenol—Syncope—Irinotecan—colon cancer	0.00155	0.0026	CcSEcCtD
Epoprostenol—Anaemia—Fluorouracil—colon cancer	0.00153	0.00257	CcSEcCtD
Epoprostenol—Loss of consciousness—Irinotecan—colon cancer	0.00152	0.00255	CcSEcCtD
Epoprostenol—Myalgia—Vincristine—colon cancer	0.00151	0.00254	CcSEcCtD
Epoprostenol—Cough—Irinotecan—colon cancer	0.00151	0.00253	CcSEcCtD
Epoprostenol—Weight decreased—Capecitabine—colon cancer	0.0015	0.00252	CcSEcCtD
Epoprostenol—Pneumonia—Capecitabine—colon cancer	0.00149	0.0025	CcSEcCtD
Epoprostenol—Infestation NOS—Capecitabine—colon cancer	0.00148	0.00249	CcSEcCtD
Epoprostenol—Infestation—Capecitabine—colon cancer	0.00148	0.00249	CcSEcCtD
Epoprostenol—Depression—Capecitabine—colon cancer	0.00148	0.00248	CcSEcCtD
Epoprostenol—Acute coronary syndrome—Capecitabine—colon cancer	0.00146	0.00245	CcSEcCtD
Epoprostenol—Myocardial infarction—Capecitabine—colon cancer	0.00145	0.00244	CcSEcCtD
Epoprostenol—Anaphylactic shock—Vincristine—colon cancer	0.00145	0.00243	CcSEcCtD
Epoprostenol—Oedema—Vincristine—colon cancer	0.00145	0.00243	CcSEcCtD
Epoprostenol—Infection—Vincristine—colon cancer	0.00144	0.00242	CcSEcCtD
Epoprostenol—Urinary tract infection—Capecitabine—colon cancer	0.00144	0.00242	CcSEcCtD
Epoprostenol—Confusional state—Irinotecan—colon cancer	0.00142	0.00239	CcSEcCtD
Epoprostenol—Nervous system disorder—Vincristine—colon cancer	0.00142	0.00239	CcSEcCtD
Epoprostenol—PTGIS—Eicosanoid Synthesis—PTGS2—colon cancer	0.00142	0.0445	CbGpPWpGaD
Epoprostenol—Thrombocytopenia—Vincristine—colon cancer	0.00142	0.00238	CcSEcCtD
Epoprostenol—Haematuria—Capecitabine—colon cancer	0.00141	0.00237	CcSEcCtD
Epoprostenol—Anaphylactic shock—Irinotecan—colon cancer	0.00141	0.00237	CcSEcCtD
Epoprostenol—Oedema—Irinotecan—colon cancer	0.00141	0.00237	CcSEcCtD
Epoprostenol—Chest pain—Fluorouracil—colon cancer	0.00141	0.00237	CcSEcCtD
Epoprostenol—Myalgia—Fluorouracil—colon cancer	0.00141	0.00237	CcSEcCtD
Epoprostenol—Infection—Irinotecan—colon cancer	0.0014	0.00235	CcSEcCtD
Epoprostenol—Hyperhidrosis—Vincristine—colon cancer	0.0014	0.00235	CcSEcCtD
Epoprostenol—Epistaxis—Capecitabine—colon cancer	0.0014	0.00234	CcSEcCtD
Epoprostenol—Shock—Irinotecan—colon cancer	0.00139	0.00233	CcSEcCtD
Epoprostenol—Nervous system disorder—Irinotecan—colon cancer	0.00138	0.00232	CcSEcCtD
Epoprostenol—Thrombocytopenia—Irinotecan—colon cancer	0.00138	0.00232	CcSEcCtD
Epoprostenol—Anorexia—Vincristine—colon cancer	0.00138	0.00232	CcSEcCtD
Epoprostenol—Hyperhidrosis—Irinotecan—colon cancer	0.00136	0.00229	CcSEcCtD
Epoprostenol—Confusional state—Fluorouracil—colon cancer	0.00136	0.00229	CcSEcCtD
Epoprostenol—Hypotension—Vincristine—colon cancer	0.00135	0.00227	CcSEcCtD
Epoprostenol—Bradycardia—Capecitabine—colon cancer	0.00135	0.00227	CcSEcCtD
Epoprostenol—Oedema—Fluorouracil—colon cancer	0.00135	0.00227	CcSEcCtD
Epoprostenol—Anaphylactic shock—Fluorouracil—colon cancer	0.00135	0.00227	CcSEcCtD
Epoprostenol—Anorexia—Irinotecan—colon cancer	0.00134	0.00226	CcSEcCtD
Epoprostenol—Infection—Fluorouracil—colon cancer	0.00134	0.00225	CcSEcCtD
Epoprostenol—Haemoglobin—Capecitabine—colon cancer	0.00134	0.00224	CcSEcCtD
Epoprostenol—Rhinitis—Capecitabine—colon cancer	0.00133	0.00224	CcSEcCtD
Epoprostenol—Haemorrhage—Capecitabine—colon cancer	0.00133	0.00223	CcSEcCtD
Epoprostenol—Nervous system disorder—Fluorouracil—colon cancer	0.00132	0.00222	CcSEcCtD
Epoprostenol—Thrombocytopenia—Fluorouracil—colon cancer	0.00132	0.00222	CcSEcCtD
Epoprostenol—Hypoaesthesia—Capecitabine—colon cancer	0.00132	0.00222	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Vincristine—colon cancer	0.00132	0.00222	CcSEcCtD
Epoprostenol—Pharyngitis—Capecitabine—colon cancer	0.00132	0.00221	CcSEcCtD
Epoprostenol—Tachycardia—Fluorouracil—colon cancer	0.00132	0.00221	CcSEcCtD
Epoprostenol—Hypotension—Irinotecan—colon cancer	0.00132	0.00221	CcSEcCtD
Epoprostenol—Insomnia—Vincristine—colon cancer	0.00131	0.0022	CcSEcCtD
Epoprostenol—Oedema peripheral—Capecitabine—colon cancer	0.00131	0.0022	CcSEcCtD
Epoprostenol—Connective tissue disorder—Capecitabine—colon cancer	0.00131	0.00219	CcSEcCtD
Epoprostenol—Paraesthesia—Vincristine—colon cancer	0.0013	0.00218	CcSEcCtD
Epoprostenol—Anorexia—Fluorouracil—colon cancer	0.00129	0.00216	CcSEcCtD
Epoprostenol—Insomnia—Irinotecan—colon cancer	0.00128	0.00214	CcSEcCtD
Epoprostenol—Paraesthesia—Irinotecan—colon cancer	0.00127	0.00213	CcSEcCtD
Epoprostenol—Hypotension—Fluorouracil—colon cancer	0.00126	0.00212	CcSEcCtD
Epoprostenol—Decreased appetite—Vincristine—colon cancer	0.00126	0.00211	CcSEcCtD
Epoprostenol—Dyspnoea—Irinotecan—colon cancer	0.00126	0.00211	CcSEcCtD
Epoprostenol—Somnolence—Irinotecan—colon cancer	0.00125	0.00211	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Vincristine—colon cancer	0.00125	0.0021	CcSEcCtD
Epoprostenol—Fatigue—Vincristine—colon cancer	0.00125	0.0021	CcSEcCtD
Epoprostenol—Dyspepsia—Irinotecan—colon cancer	0.00124	0.00209	CcSEcCtD
Epoprostenol—Constipation—Vincristine—colon cancer	0.00124	0.00208	CcSEcCtD
Epoprostenol—Pain—Vincristine—colon cancer	0.00124	0.00208	CcSEcCtD
Epoprostenol—Cardiac disorder—Capecitabine—colon cancer	0.00123	0.00207	CcSEcCtD
Epoprostenol—Flushing—Capecitabine—colon cancer	0.00123	0.00207	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00123	0.00207	CcSEcCtD
Epoprostenol—Decreased appetite—Irinotecan—colon cancer	0.00123	0.00206	CcSEcCtD
Epoprostenol—Insomnia—Fluorouracil—colon cancer	0.00122	0.00205	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Irinotecan—colon cancer	0.00122	0.00204	CcSEcCtD
Epoprostenol—Fatigue—Irinotecan—colon cancer	0.00122	0.00204	CcSEcCtD
Epoprostenol—Paraesthesia—Fluorouracil—colon cancer	0.00121	0.00204	CcSEcCtD
Epoprostenol—Pain—Irinotecan—colon cancer	0.00121	0.00203	CcSEcCtD
Epoprostenol—Constipation—Irinotecan—colon cancer	0.00121	0.00203	CcSEcCtD
Epoprostenol—Angiopathy—Capecitabine—colon cancer	0.00121	0.00202	CcSEcCtD
Epoprostenol—Dyspnoea—Fluorouracil—colon cancer	0.0012	0.00202	CcSEcCtD
Epoprostenol—Somnolence—Fluorouracil—colon cancer	0.0012	0.00202	CcSEcCtD
Epoprostenol—Mediastinal disorder—Capecitabine—colon cancer	0.0012	0.00201	CcSEcCtD
Epoprostenol—Chills—Capecitabine—colon cancer	0.00119	0.002	CcSEcCtD
Epoprostenol—Dyspepsia—Fluorouracil—colon cancer	0.00119	0.002	CcSEcCtD
Epoprostenol—PTGIS—Prostaglandin Synthesis and Regulation—PTGS2—colon cancer	0.00119	0.0373	CbGpPWpGaD
Epoprostenol—Abdominal discomfort—Methotrexate—colon cancer	0.00118	0.00199	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Vincristine—colon cancer	0.00118	0.00199	CcSEcCtD
Epoprostenol—Decreased appetite—Fluorouracil—colon cancer	0.00117	0.00197	CcSEcCtD
Epoprostenol—Pancytopenia—Methotrexate—colon cancer	0.00117	0.00197	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Fluorouracil—colon cancer	0.00117	0.00196	CcSEcCtD
Epoprostenol—Mental disorder—Capecitabine—colon cancer	0.00116	0.00195	CcSEcCtD
Epoprostenol—Pain—Fluorouracil—colon cancer	0.00116	0.00194	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Irinotecan—colon cancer	0.00115	0.00194	CcSEcCtD
Epoprostenol—Body temperature increased—Vincristine—colon cancer	0.00114	0.00192	CcSEcCtD
Epoprostenol—Abdominal pain—Vincristine—colon cancer	0.00114	0.00192	CcSEcCtD
Epoprostenol—Flatulence—Capecitabine—colon cancer	0.00114	0.00191	CcSEcCtD
Epoprostenol—Back pain—Capecitabine—colon cancer	0.00112	0.00188	CcSEcCtD
Epoprostenol—Abdominal pain—Irinotecan—colon cancer	0.00111	0.00187	CcSEcCtD
Epoprostenol—Body temperature increased—Irinotecan—colon cancer	0.00111	0.00187	CcSEcCtD
Epoprostenol—Muscle spasms—Capecitabine—colon cancer	0.00111	0.00187	CcSEcCtD
Epoprostenol—Pneumonia—Methotrexate—colon cancer	0.00111	0.00186	CcSEcCtD
Epoprostenol—Infestation—Methotrexate—colon cancer	0.0011	0.00185	CcSEcCtD
Epoprostenol—Infestation NOS—Methotrexate—colon cancer	0.0011	0.00185	CcSEcCtD
Epoprostenol—Depression—Methotrexate—colon cancer	0.0011	0.00185	CcSEcCtD
Epoprostenol—Tremor—Capecitabine—colon cancer	0.00108	0.00182	CcSEcCtD
Epoprostenol—Urticaria—Fluorouracil—colon cancer	0.00107	0.0018	CcSEcCtD
Epoprostenol—Anaemia—Capecitabine—colon cancer	0.00107	0.0018	CcSEcCtD
Epoprostenol—Body temperature increased—Fluorouracil—colon cancer	0.00107	0.00179	CcSEcCtD
Epoprostenol—Hypersensitivity—Vincristine—colon cancer	0.00107	0.00179	CcSEcCtD
Epoprostenol—Sweating—Methotrexate—colon cancer	0.00106	0.00177	CcSEcCtD
Epoprostenol—Haematuria—Methotrexate—colon cancer	0.00105	0.00176	CcSEcCtD
Epoprostenol—Epistaxis—Methotrexate—colon cancer	0.00104	0.00175	CcSEcCtD
Epoprostenol—Hypersensitivity—Irinotecan—colon cancer	0.00104	0.00175	CcSEcCtD
Epoprostenol—Asthenia—Vincristine—colon cancer	0.00104	0.00175	CcSEcCtD
Epoprostenol—Syncope—Capecitabine—colon cancer	0.00104	0.00174	CcSEcCtD
Epoprostenol—Palpitations—Capecitabine—colon cancer	0.00102	0.00172	CcSEcCtD
Epoprostenol—Loss of consciousness—Capecitabine—colon cancer	0.00102	0.00171	CcSEcCtD
Epoprostenol—Asthenia—Irinotecan—colon cancer	0.00101	0.0017	CcSEcCtD
Epoprostenol—Cough—Capecitabine—colon cancer	0.00101	0.0017	CcSEcCtD
Epoprostenol—Hypersensitivity—Fluorouracil—colon cancer	0.000995	0.00167	CcSEcCtD
Epoprostenol—Haemoglobin—Methotrexate—colon cancer	0.000994	0.00167	CcSEcCtD
Epoprostenol—Diarrhoea—Vincristine—colon cancer	0.000991	0.00166	CcSEcCtD
Epoprostenol—Haemorrhage—Methotrexate—colon cancer	0.000989	0.00166	CcSEcCtD
Epoprostenol—Chest pain—Capecitabine—colon cancer	0.000985	0.00165	CcSEcCtD
Epoprostenol—Myalgia—Capecitabine—colon cancer	0.000985	0.00165	CcSEcCtD
Epoprostenol—Arthralgia—Capecitabine—colon cancer	0.000985	0.00165	CcSEcCtD
Epoprostenol—Pharyngitis—Methotrexate—colon cancer	0.000982	0.00165	CcSEcCtD
Epoprostenol—Anxiety—Capecitabine—colon cancer	0.000981	0.00165	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000978	0.00164	CcSEcCtD
Epoprostenol—Diarrhoea—Irinotecan—colon cancer	0.000965	0.00162	CcSEcCtD
Epoprostenol—Dry mouth—Capecitabine—colon cancer	0.000963	0.00162	CcSEcCtD
Epoprostenol—Dizziness—Vincristine—colon cancer	0.000958	0.00161	CcSEcCtD
Epoprostenol—Pruritus—Fluorouracil—colon cancer	0.000956	0.00161	CcSEcCtD
Epoprostenol—Confusional state—Capecitabine—colon cancer	0.000952	0.0016	CcSEcCtD
Epoprostenol—Oedema—Capecitabine—colon cancer	0.000944	0.00159	CcSEcCtD
Epoprostenol—Infection—Capecitabine—colon cancer	0.000938	0.00157	CcSEcCtD
Epoprostenol—Dizziness—Irinotecan—colon cancer	0.000933	0.00157	CcSEcCtD
Epoprostenol—Shock—Capecitabine—colon cancer	0.000929	0.00156	CcSEcCtD
Epoprostenol—Nervous system disorder—Capecitabine—colon cancer	0.000926	0.00155	CcSEcCtD
Epoprostenol—Diarrhoea—Fluorouracil—colon cancer	0.000924	0.00155	CcSEcCtD
Epoprostenol—Thrombocytopenia—Capecitabine—colon cancer	0.000924	0.00155	CcSEcCtD
Epoprostenol—Tachycardia—Capecitabine—colon cancer	0.000921	0.00155	CcSEcCtD
Epoprostenol—Vomiting—Vincristine—colon cancer	0.000921	0.00155	CcSEcCtD
Epoprostenol—Cardiac disorder—Methotrexate—colon cancer	0.000918	0.00154	CcSEcCtD
Epoprostenol—Skin disorder—Capecitabine—colon cancer	0.000917	0.00154	CcSEcCtD
Epoprostenol—Rash—Vincristine—colon cancer	0.000913	0.00153	CcSEcCtD
Epoprostenol—Hyperhidrosis—Capecitabine—colon cancer	0.000912	0.00153	CcSEcCtD
Epoprostenol—Dermatitis—Vincristine—colon cancer	0.000912	0.00153	CcSEcCtD
Epoprostenol—Headache—Vincristine—colon cancer	0.000907	0.00152	CcSEcCtD
Epoprostenol—Anorexia—Capecitabine—colon cancer	0.0009	0.00151	CcSEcCtD
Epoprostenol—Angiopathy—Methotrexate—colon cancer	0.000897	0.00151	CcSEcCtD
Epoprostenol—Vomiting—Irinotecan—colon cancer	0.000897	0.00151	CcSEcCtD
Epoprostenol—Dizziness—Fluorouracil—colon cancer	0.000893	0.0015	CcSEcCtD
Epoprostenol—Mediastinal disorder—Methotrexate—colon cancer	0.000891	0.0015	CcSEcCtD
Epoprostenol—Rash—Irinotecan—colon cancer	0.000889	0.00149	CcSEcCtD
Epoprostenol—Dermatitis—Irinotecan—colon cancer	0.000888	0.00149	CcSEcCtD
Epoprostenol—Chills—Methotrexate—colon cancer	0.000887	0.00149	CcSEcCtD
Epoprostenol—Headache—Irinotecan—colon cancer	0.000883	0.00148	CcSEcCtD
Epoprostenol—Hypotension—Capecitabine—colon cancer	0.000882	0.00148	CcSEcCtD
Epoprostenol—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—colon cancer	0.000869	0.0273	CbGpPWpGaD
Epoprostenol—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—colon cancer	0.000869	0.0273	CbGpPWpGaD
Epoprostenol—Mental disorder—Methotrexate—colon cancer	0.000866	0.00146	CcSEcCtD
Epoprostenol—Nausea—Vincristine—colon cancer	0.00086	0.00144	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00086	0.00144	CcSEcCtD
Epoprostenol—Vomiting—Fluorouracil—colon cancer	0.000859	0.00144	CcSEcCtD
Epoprostenol—Insomnia—Capecitabine—colon cancer	0.000854	0.00143	CcSEcCtD
Epoprostenol—Rash—Fluorouracil—colon cancer	0.000852	0.00143	CcSEcCtD
Epoprostenol—Dermatitis—Fluorouracil—colon cancer	0.000851	0.00143	CcSEcCtD
Epoprostenol—Paraesthesia—Capecitabine—colon cancer	0.000848	0.00142	CcSEcCtD
Epoprostenol—Headache—Fluorouracil—colon cancer	0.000846	0.00142	CcSEcCtD
Epoprostenol—Dyspnoea—Capecitabine—colon cancer	0.000842	0.00141	CcSEcCtD
Epoprostenol—Nausea—Irinotecan—colon cancer	0.000838	0.00141	CcSEcCtD
Epoprostenol—Back pain—Methotrexate—colon cancer	0.000833	0.0014	CcSEcCtD
Epoprostenol—Dyspepsia—Capecitabine—colon cancer	0.000831	0.0014	CcSEcCtD
Epoprostenol—Decreased appetite—Capecitabine—colon cancer	0.000821	0.00138	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Capecitabine—colon cancer	0.000815	0.00137	CcSEcCtD
Epoprostenol—Fatigue—Capecitabine—colon cancer	0.000814	0.00137	CcSEcCtD
Epoprostenol—Constipation—Capecitabine—colon cancer	0.000807	0.00136	CcSEcCtD
Epoprostenol—Pain—Capecitabine—colon cancer	0.000807	0.00136	CcSEcCtD
Epoprostenol—Nausea—Fluorouracil—colon cancer	0.000802	0.00135	CcSEcCtD
Epoprostenol—Anaemia—Methotrexate—colon cancer	0.000796	0.00134	CcSEcCtD
Epoprostenol—PTGIS—Arachidonic acid metabolism—PTGS2—colon cancer	0.000789	0.0248	CbGpPWpGaD
Epoprostenol—Gastrointestinal pain—Capecitabine—colon cancer	0.000772	0.0013	CcSEcCtD
Epoprostenol—Cough—Methotrexate—colon cancer	0.000751	0.00126	CcSEcCtD
Epoprostenol—Urticaria—Capecitabine—colon cancer	0.00075	0.00126	CcSEcCtD
Epoprostenol—Body temperature increased—Capecitabine—colon cancer	0.000746	0.00125	CcSEcCtD
Epoprostenol—Abdominal pain—Capecitabine—colon cancer	0.000746	0.00125	CcSEcCtD
Epoprostenol—P2RY12—Signal amplification—SRC—colon cancer	0.000744	0.0233	CbGpPWpGaD
Epoprostenol—Chest pain—Methotrexate—colon cancer	0.000733	0.00123	CcSEcCtD
Epoprostenol—Arthralgia—Methotrexate—colon cancer	0.000733	0.00123	CcSEcCtD
Epoprostenol—Myalgia—Methotrexate—colon cancer	0.000733	0.00123	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000728	0.00122	CcSEcCtD
Epoprostenol—Confusional state—Methotrexate—colon cancer	0.000708	0.00119	CcSEcCtD
Epoprostenol—CYP2C9—Metapathway biotransformation—CHST4—colon cancer	0.000705	0.0221	CbGpPWpGaD
Epoprostenol—Anaphylactic shock—Methotrexate—colon cancer	0.000703	0.00118	CcSEcCtD
Epoprostenol—Infection—Methotrexate—colon cancer	0.000698	0.00117	CcSEcCtD
Epoprostenol—Hypersensitivity—Capecitabine—colon cancer	0.000695	0.00117	CcSEcCtD
Epoprostenol—Nervous system disorder—Methotrexate—colon cancer	0.000689	0.00116	CcSEcCtD
Epoprostenol—Thrombocytopenia—Methotrexate—colon cancer	0.000688	0.00116	CcSEcCtD
Epoprostenol—Skin disorder—Methotrexate—colon cancer	0.000683	0.00115	CcSEcCtD
Epoprostenol—Hyperhidrosis—Methotrexate—colon cancer	0.000679	0.00114	CcSEcCtD
Epoprostenol—Asthenia—Capecitabine—colon cancer	0.000677	0.00114	CcSEcCtD
Epoprostenol—Anorexia—Methotrexate—colon cancer	0.00067	0.00112	CcSEcCtD
Epoprostenol—Pruritus—Capecitabine—colon cancer	0.000668	0.00112	CcSEcCtD
Epoprostenol—Hypotension—Methotrexate—colon cancer	0.000657	0.0011	CcSEcCtD
Epoprostenol—Diarrhoea—Capecitabine—colon cancer	0.000646	0.00108	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00064	0.00108	CcSEcCtD
Epoprostenol—Insomnia—Methotrexate—colon cancer	0.000636	0.00107	CcSEcCtD
Epoprostenol—Paraesthesia—Methotrexate—colon cancer	0.000631	0.00106	CcSEcCtD
Epoprostenol—Dyspnoea—Methotrexate—colon cancer	0.000626	0.00105	CcSEcCtD
Epoprostenol—Somnolence—Methotrexate—colon cancer	0.000625	0.00105	CcSEcCtD
Epoprostenol—Dizziness—Capecitabine—colon cancer	0.000624	0.00105	CcSEcCtD
Epoprostenol—Dyspepsia—Methotrexate—colon cancer	0.000619	0.00104	CcSEcCtD
Epoprostenol—Decreased appetite—Methotrexate—colon cancer	0.000611	0.00103	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Methotrexate—colon cancer	0.000607	0.00102	CcSEcCtD
Epoprostenol—Fatigue—Methotrexate—colon cancer	0.000606	0.00102	CcSEcCtD
Epoprostenol—Pain—Methotrexate—colon cancer	0.000601	0.00101	CcSEcCtD
Epoprostenol—Vomiting—Capecitabine—colon cancer	0.0006	0.00101	CcSEcCtD
Epoprostenol—Rash—Capecitabine—colon cancer	0.000595	0.001	CcSEcCtD
Epoprostenol—Dermatitis—Capecitabine—colon cancer	0.000595	0.000999	CcSEcCtD
Epoprostenol—Headache—Capecitabine—colon cancer	0.000591	0.000993	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Methotrexate—colon cancer	0.000575	0.000965	CcSEcCtD
Epoprostenol—PTGIS—Metabolism—CA7—colon cancer	0.000573	0.018	CbGpPWpGaD
Epoprostenol—Nausea—Capecitabine—colon cancer	0.000561	0.000942	CcSEcCtD
Epoprostenol—Urticaria—Methotrexate—colon cancer	0.000558	0.000938	CcSEcCtD
Epoprostenol—Body temperature increased—Methotrexate—colon cancer	0.000555	0.000933	CcSEcCtD
Epoprostenol—Abdominal pain—Methotrexate—colon cancer	0.000555	0.000933	CcSEcCtD
Epoprostenol—Hypersensitivity—Methotrexate—colon cancer	0.000518	0.000869	CcSEcCtD
Epoprostenol—PTGIS—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—colon cancer	0.000507	0.0159	CbGpPWpGaD
Epoprostenol—Asthenia—Methotrexate—colon cancer	0.000504	0.000847	CcSEcCtD
Epoprostenol—Pruritus—Methotrexate—colon cancer	0.000497	0.000835	CcSEcCtD
Epoprostenol—Diarrhoea—Methotrexate—colon cancer	0.000481	0.000807	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—PPARG—colon cancer	0.000467	0.0147	CbGpPWpGaD
Epoprostenol—Dizziness—Methotrexate—colon cancer	0.000465	0.00078	CcSEcCtD
Epoprostenol—Vomiting—Methotrexate—colon cancer	0.000447	0.00075	CcSEcCtD
Epoprostenol—Rash—Methotrexate—colon cancer	0.000443	0.000744	CcSEcCtD
Epoprostenol—Dermatitis—Methotrexate—colon cancer	0.000443	0.000743	CcSEcCtD
Epoprostenol—Headache—Methotrexate—colon cancer	0.00044	0.000739	CcSEcCtD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—SRC—colon cancer	0.000427	0.0134	CbGpPWpGaD
Epoprostenol—Nausea—Methotrexate—colon cancer	0.000417	0.000701	CcSEcCtD
Epoprostenol—PTGIS—Disease—LGR5—colon cancer	0.000415	0.013	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CHST5—colon cancer	0.000415	0.013	CbGpPWpGaD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—EGFR—colon cancer	0.000374	0.0117	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ODC1—colon cancer	0.000347	0.0109	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—CHST5—colon cancer	0.000347	0.0109	CbGpPWpGaD
Epoprostenol—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000333	0.0104	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—CTNNB1—colon cancer	0.000329	0.0103	CbGpPWpGaD
Epoprostenol—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	0.000324	0.0102	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—CDKN1A—colon cancer	0.000321	0.0101	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000317	0.00995	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AXIN2—colon cancer	0.000298	0.00935	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—TGFB1—colon cancer	0.000266	0.00833	CbGpPWpGaD
Epoprostenol—PTGIR—Thromboxane A2 receptor signaling—AKT1—colon cancer	0.000265	0.00832	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—DLC1—colon cancer	0.000246	0.00771	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—LGR5—colon cancer	0.000231	0.00725	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—DLC1—colon cancer	0.000226	0.00709	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—DLC1—colon cancer	0.000226	0.00709	CbGpPWpGaD
Epoprostenol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000221	0.00692	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—LGR5—colon cancer	0.000213	0.00667	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—LGR5—colon cancer	0.000213	0.00667	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AXIN2—colon cancer	0.000166	0.00521	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—SRC—colon cancer	0.000155	0.00485	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AXIN2—colon cancer	0.000153	0.00479	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AXIN2—colon cancer	0.000153	0.00479	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—VEGFA—colon cancer	0.000151	0.00472	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PPARG—colon cancer	0.000143	0.0045	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—colon cancer	0.00014	0.00439	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—TGFB1—colon cancer	0.000138	0.00434	CbGpPWpGaD
Epoprostenol—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	0.000128	0.004	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—colon cancer	0.000127	0.004	CbGpPWpGaD
Epoprostenol—PTGER1—G alpha (q) signalling events—PIK3CA—colon cancer	0.000124	0.00388	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—colon cancer	0.00012	0.00378	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	0.000118	0.00369	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	0.000113	0.00354	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—colon cancer	0.000111	0.00347	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—colon cancer	0.000102	0.00321	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—AKT1—colon cancer	9.61e-05	0.00301	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.38e-05	0.00294	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CA7—colon cancer	9.26e-05	0.00291	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ABCB1—colon cancer	9.18e-05	0.00288	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—TYMS—colon cancer	9.01e-05	0.00283	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—FGFR3—colon cancer	8.6e-05	0.0027	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—EP300—colon cancer	8.19e-05	0.00257	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—SRC—colon cancer	7.97e-05	0.0025	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—APC—colon cancer	7.9e-05	0.00248	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—VEGFA—colon cancer	7.76e-05	0.00243	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—NRAS—colon cancer	7.67e-05	0.0024	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—EP300—colon cancer	7.54e-05	0.00237	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—BRAF—colon cancer	7.43e-05	0.00233	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—SRC—colon cancer	7.33e-05	0.0023	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—VEGFA—colon cancer	7.14e-05	0.00224	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TGFB1—colon cancer	7.12e-05	0.00223	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—NRAS—colon cancer	7.06e-05	0.00221	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.94e-05	0.00218	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—KRAS—colon cancer	6.6e-05	0.00207	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TGFB1—colon cancer	6.56e-05	0.00206	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PPARG—colon cancer	6.39e-05	0.002	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—KRAS—colon cancer	6.07e-05	0.0019	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—PIK3CA—colon cancer	6.06e-05	0.0019	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PTGS2—colon cancer	6e-05	0.00188	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—TP53—colon cancer	5.86e-05	0.00184	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ODC1—colon cancer	5.61e-05	0.00176	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—CHST5—colon cancer	5.61e-05	0.00176	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—HRAS—colon cancer	5.61e-05	0.00176	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—PIK3CA—colon cancer	5.58e-05	0.00175	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—TP53—colon cancer	5.4e-05	0.00169	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CTNNB1—colon cancer	5.37e-05	0.00168	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CDKN1A—colon cancer	5.24e-05	0.00164	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—HRAS—colon cancer	5.16e-05	0.00162	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PTGS2—colon cancer	5.02e-05	0.00158	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EP300—colon cancer	4.99e-05	0.00156	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—AKT1—colon cancer	4.95e-05	0.00155	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—SRC—colon cancer	4.85e-05	0.00152	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—FGFR3—colon cancer	4.79e-05	0.0015	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—NRAS—colon cancer	4.67e-05	0.00146	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—AKT1—colon cancer	4.56e-05	0.00143	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—FGFR3—colon cancer	4.41e-05	0.00138	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—FGFR3—colon cancer	4.41e-05	0.00138	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—APC—colon cancer	4.4e-05	0.00138	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—NRAS—colon cancer	4.4e-05	0.00138	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—MYC—colon cancer	4.35e-05	0.00136	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—TGFB1—colon cancer	4.34e-05	0.00136	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—EGFR—colon cancer	4.25e-05	0.00133	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—EP300—colon cancer	4.18e-05	0.00131	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—BRAF—colon cancer	4.14e-05	0.0013	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—APC—colon cancer	4.05e-05	0.00127	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—APC—colon cancer	4.05e-05	0.00127	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—NRAS—colon cancer	4.05e-05	0.00127	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—NRAS—colon cancer	4.05e-05	0.00127	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—KRAS—colon cancer	4.02e-05	0.00126	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—EGFR—colon cancer	4.01e-05	0.00126	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—PIK3CA—colon cancer	3.83e-05	0.0012	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—BRAF—colon cancer	3.81e-05	0.00119	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—BRAF—colon cancer	3.81e-05	0.00119	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—KRAS—colon cancer	3.79e-05	0.00119	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—PIK3CA—colon cancer	3.69e-05	0.00116	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—EGFR—colon cancer	3.69e-05	0.00116	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—EGFR—colon cancer	3.69e-05	0.00116	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—PIK3CA—colon cancer	3.53e-05	0.00111	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—PIK3CA—colon cancer	3.53e-05	0.00111	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—KRAS—colon cancer	3.48e-05	0.00109	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—KRAS—colon cancer	3.48e-05	0.00109	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—PIK3CA—colon cancer	3.48e-05	0.00109	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—HRAS—colon cancer	3.41e-05	0.00107	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—HRAS—colon cancer	3.22e-05	0.00101	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—PIK3CA—colon cancer	3.2e-05	0.001	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—PIK3CA—colon cancer	3.2e-05	0.001	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—AKT1—colon cancer	3.13e-05	0.000982	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CASP3—colon cancer	3.1e-05	0.000973	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—PIK3CA—colon cancer	3.09e-05	0.000969	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCND1—colon cancer	3.02e-05	0.000947	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—AKT1—colon cancer	3.01e-05	0.000946	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CTNNB1—colon cancer	2.99e-05	0.000938	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—HRAS—colon cancer	2.96e-05	0.000929	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—HRAS—colon cancer	2.96e-05	0.000929	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CDKN1A—colon cancer	2.92e-05	0.000916	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—AKT1—colon cancer	2.88e-05	0.000904	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—AKT1—colon cancer	2.88e-05	0.000904	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CASP3—colon cancer	2.85e-05	0.000895	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CASP3—colon cancer	2.85e-05	0.000895	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—AKT1—colon cancer	2.84e-05	0.000892	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EP300—colon cancer	2.78e-05	0.000872	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCND1—colon cancer	2.78e-05	0.000871	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCND1—colon cancer	2.78e-05	0.000871	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CTNNB1—colon cancer	2.75e-05	0.000863	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CTNNB1—colon cancer	2.75e-05	0.000863	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—SRC—colon cancer	2.7e-05	0.000848	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CDKN1A—colon cancer	2.69e-05	0.000843	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CDKN1A—colon cancer	2.69e-05	0.000843	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—VEGFA—colon cancer	2.63e-05	0.000825	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—AKT1—colon cancer	2.62e-05	0.00082	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—AKT1—colon cancer	2.62e-05	0.00082	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—NRAS—colon cancer	2.6e-05	0.000815	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EP300—colon cancer	2.56e-05	0.000802	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EP300—colon cancer	2.56e-05	0.000802	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AKT1—colon cancer	2.52e-05	0.000792	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—SRC—colon cancer	2.49e-05	0.00078	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—SRC—colon cancer	2.49e-05	0.00078	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—VEGFA—colon cancer	2.42e-05	0.00076	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—VEGFA—colon cancer	2.42e-05	0.00076	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—MYC—colon cancer	2.42e-05	0.000759	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TGFB1—colon cancer	2.42e-05	0.000758	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—NRAS—colon cancer	2.39e-05	0.00075	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—NRAS—colon cancer	2.39e-05	0.00075	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—EGFR—colon cancer	2.37e-05	0.000743	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.32e-05	0.000727	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—KRAS—colon cancer	2.24e-05	0.000702	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—MYC—colon cancer	2.23e-05	0.000699	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—MYC—colon cancer	2.23e-05	0.000699	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TGFB1—colon cancer	2.22e-05	0.000697	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TGFB1—colon cancer	2.22e-05	0.000697	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—EGFR—colon cancer	2.18e-05	0.000684	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—EGFR—colon cancer	2.18e-05	0.000684	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—KRAS—colon cancer	2.06e-05	0.000646	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—KRAS—colon cancer	2.06e-05	0.000646	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—PIK3CA—colon cancer	2.06e-05	0.000645	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—TP53—colon cancer	1.99e-05	0.000624	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—HRAS—colon cancer	1.9e-05	0.000596	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—PIK3CA—colon cancer	1.89e-05	0.000593	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—PIK3CA—colon cancer	1.89e-05	0.000593	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—TP53—colon cancer	1.83e-05	0.000574	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—TP53—colon cancer	1.83e-05	0.000574	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.82e-05	0.000572	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—HRAS—colon cancer	1.75e-05	0.000549	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—HRAS—colon cancer	1.75e-05	0.000549	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—AKT1—colon cancer	1.68e-05	0.000527	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—AKT1—colon cancer	1.55e-05	0.000485	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—AKT1—colon cancer	1.55e-05	0.000485	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.52e-05	0.000476	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ABCB1—colon cancer	1.48e-05	0.000465	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TYMS—colon cancer	1.46e-05	0.000457	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.12e-05	0.000352	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PPARG—colon cancer	1.03e-05	0.000324	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PTGS2—colon cancer	8.12e-06	0.000255	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—EP300—colon cancer	6.75e-06	0.000212	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—PIK3CA—colon cancer	4.99e-06	0.000157	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AKT1—colon cancer	4.08e-06	0.000128	CbGpPWpGaD
